Fig. 2: STING agonist-adjuvanted RBD-Fc induces robust cross-neutralizing antibodies against multiple sarbecoviruses in mice. | Cell Research

Fig. 2: STING agonist-adjuvanted RBD-Fc induces robust cross-neutralizing antibodies against multiple sarbecoviruses in mice.

From: A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Fig. 2

a, b Neutralization activity of sera from mice immunized with RBD-Fc formulated with the indicated adjuvants against SARS-CoV-2 PsV at day 21 (a) and day 35 (b). Data are shown as geometric means ± SD from six samples. c, d Correlation between SARS-CoV-2 RBD-binding IgG endpoint titers and the NT50 against SARS-CoV-2 PsV in serum at day 21 (c) and day 35 (d). e, f Dose-dependent inhibitory activity of the pooled sera from indicated mouse groups against authentic SARS-CoV-2 (strain: SH01) infection at day 21 (e) and day 35 (f). Data are shown as means ± SEM. g Comparison of the RBD protein structures of SARS-CoV-2 (WT), SARS-CoV-2 (B.1.1.7), and SARS-CoV. h–j Cross-neutralization activity against SARS-CoV PsV (h), SARSr-CoV Rs3367 (i) and SARSr-CoV WIV1 (j) on day 35. Data shown are geometric means ± SD from six samples. Statistical analyses were performed using one-way ANOVA for comparison of the neutralization antibody titers. *P < 0.05, **P < 0.001, ***P < 0.0001. Spearman rank test was used to perform the correlation analysis.

Back to article page